PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2026Drug Design Development and Therapy0 citationsOpen Access

Mechanisms and Drug-Augmenting Strategies of Mesenchymal Stem Cells for Preserving β-Cell in Type 2 Diabetes

KWKunlu WangJLJiuwei LiCHCong Han

Key Points

  • This review aims to explore the protective mechanisms of mesenchymal stem cells for preserving β-cell function in type 2 diabetes.
  • Systematic review of mechanisms by which MSCs protect pancreatic β-cells.
  • Examination of pharmacological strategies that enhance MSC efficacy.
  • Evaluation of existing research limitations and future research directions.
  • Identified eight core mechanisms through which MSCs preserve β-cell function.
  • Highlighted the synergistic effects of pharmacological agents in enhancing MSC performance.
  • Proposed recommendations for optimizing MSC source selection and engineering MSC-derived exosomes.

Abstract

Abstract: Type 2 diabetes (T2D) is closely linked to β-cell dysfunction. Preserving β-cell function has emerged as a critical therapeutic strategy for T2D. Mesenchymal stem cells (MSCs) have demonstrated remarkable potential in achieving this goal. This paper systematically reviews the multifaceted mechanisms by which MSCs protect pancreatic β-cell function in T2D. It integrates eight core mechanisms: modulating the inflammatory microenvironment, regulating the immune system, counteracting oxidative stress, enhancing autophagy levels, alleviating endoplasmic reticulum stress, safeguarding mitochondrial function, promoting β-cell regeneration and repair, and inhibiting ferroptosis. Together, these form a multi-layered, networked intervention system. This framework elucidates MSC protective effects across three functional levels: eliminating injury initiators, maintaining cellular homeostasis, and intervening in cellular fate outcomes. Additionally, this review examines pharmacological strategies to enhance MSC efficacy, including hypoglycemic agents, other drugs, and natural products, with a focus on their mechanisms of action and barriers to clinical translation. Finally, based on MSC advantages and existing research limitations, we propose future research directions, including optimizing MSC source selection and engineering MSC-derived exosomes. These recommendations aim to provide theoretical foundations and strategic references for MSC-based T2D therapies. At the top, the text reads ’Hyperglycemic conditions’. On the left, an image of a medicine pack is labeled ’pharmacological agents’, with arrows indicating ’protect’, ’enhance’ and ’modulate’ effects on ’mesenchymal stem cells’. These cells are depicted as a cluster of circular shapes. From the stem cells, lines extend to the right, connecting to various processes affecting beta-cells, shown as a cluster of smaller circular shapes. The processes listed are ’inflammation’, ’immunity’, ’regeneration and apoptosis’, ’ferroptosis’, ’autophagy’, ’oxidative stress’, ’endoplasmic reticulum stress’ and ’mitochondrial function’.In a hyperglycemic environment, the pharmacological agent can protect MSCs and enhance the protective effects of MSCs on β-cells. Keywords: mesenchymal stem cells, type 2 diabetes, β-cell, hypoglycemic agents, natural products

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69e9b85585696592c86eba14https://doi.org/10.2147/dddt.s586404
Ask AI
Helpful
Bookmark
Share
View Full Paper